Viola Zhu


Assistant Clinical Professor, Medicine
School of Medicine

MD PhD

Phone: (714) 456-8000
Fax: (714) 456-2242
Email: zhuvw@uci.edu

University of California, Irvine
101 The City Drive South
Building 200, Room 410
Mail Code: 4061
Orange, CA 92868
Research Interests
Lung cancer
Publications
1. Hoover DJ, Zhu V, Chen R, Briley K Jr, Rameshwar P, Cohen S, Coffman FD. Expression of the chitinase family glycoprotein YKL-40 in undifferentiated, differentiated and trans-differentiated mesenchymal stem cells. PLoS One 2013;8:e62491. PMID: 23671604

2. Zhu V, de las Morenas A, Janicek M, Hartshorn M. Hypercalcemia from metastatic pancreatic neuroendocrine tumor secreting 1,25-dihydroxyvitamin D. J Gastrointest Oncol 2014;5:E84-87. PMID: 25083313

3. Zhu VW, Upadhyay D, Schrock AB, Gowen K, Ali SM, Ou SH. TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling. Lung Cancer 2016;97:48-50. PMID: 27237027

4. Ou SI, Young L, Schrock AB, Johnson A, Klempner SJ, Zhu VW, Miller VA, Ali SJ. Emergence of preexisting MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET exon14 skipping. J Thorac Oncol 2017;12:137-140. PMID: 27666659

5. Reungwetwattanaa T, Liang Y, Zhu V, Ou SI. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the Why, the How, the Who, the Unknown, and the Inevitable. Lung Cancer 2017;103:27-37. PMID: 28024693

6. Zhu VW, Ou SI. ASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer. Trans Lung Cancer Res 2016;5:660-664. PMID: 28149759

7. Zhu VW, Ou SH. Safety of alectinib for the treatment of ALK-rearranged non-small cell lung cancer. Expert Opin Drug Saf 2017;16:509-14. PMID: 28276856

8. Ou SI, Lee TK, Young L, Pavlick D, Schrock AB, Ali SM, Zhu VW, Milliken J, Gitlitz BJ. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy? Lung Cancer 2017;106:110-4. PMID: 28285684

9. Zhu VW, Hinduja S, Knezevich CR, Silveira WR, DeLozier CD. A rare case of choroid plexus carcinoma that led to the diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer) spectrum. Clin Neurol Neurosurg 2017;158:46-8. PMID: 28460341

10. Ou SI, Cui J, Schrock AB, Goldberg ME, Zhu VW, Albacker L, Stephens PJ, Miller VA, Ali SM. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G769S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. Lung Cancer 2017;108:228-31. PMID: 28625641

11. Zhu VW, Cui JJ, Fernandez-Rocha M, Schrock AB, Ali SM, Ou SI. Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib. Lung Cancer 2017;110:32-4. PMID: 28676215

12. Zhu VW, Ou SI. METex14+ NSCLC: Time to take the therapy to the target to aim for a cure? J Thorac Oncol 2017;12:1180-2. PMID: 28748813

13. Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, Stephens PJ, Ross JS, Ali SM, Miller VA, Johnson ML, Lovly CM, Hata AN, Gainor JF, Iafrate AJ, Shaw AT, Ou SI. Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer. J Clin Oncol 2018;36:1199-206. PMID: 29373100

14. Nagasaka M, Zhu VW, Ou SI. The allure of ‘ALUR’. Ann Oncol 2018;29:1344-6. PMID: 29688274

15. Schrock AB, Zhu VW, Hsieh WS, Madison R, Creelan B, Silberberg J, Costin D, Bharne A, Bonta I, Bosemani T, Nikolinakos P, Ross JS, Miller VA, Ali SJ, Klempner SK, Ou SI. Receptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistant mechanisms to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2018;13:1312-23. PMID: 29883838

16. Lin JJ, Zhu VW, Schoenfeld A, Yeap BY, Saxena A, Ferris LA, Dagogo-Jack I, Farago AF, Taber A, Traynor A, Menon S, Gainor JF, Lennerz JK, Plodkowski AJ, Digumarthy SR, Ou SI, Shaw AT, Riely GJ. Brigatinib in patients with alectinib-refractory ALK-positive non-small cell lung cancer: a retrospective study. J Thorac Oncol 2018;13:1530-8. PMID: 29935304

17. Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, Zhu VW, Ahn MJ, Camidge DR, Nguyen J, Zhai D, Deng W, Huang Z, Rogers E, Liu J, Whitten J, Lim JK, Stopatschinskaja S, Hyman DM, Doebele RC, Cui JJ, Shaw AT. Ropotrectinib (TPX-0005) is a next generation ROS1/TKR/ALK inhibitor that potently inhibits ROS/TRK/ALK solvent front mutations. Cancer Discov 2018;8:1227-36. PMID: 30093503

18. Farago AF, Taylor MS, Doebele RC, Zhu VW, Kummar S, Spira AI, Boyle TA, Haura EB, Arcila ME, Benayed R, Aisner DL, Horick NK, Lennerz JK, Le LP, Iafrate AJ, Ou SI, Shaw AT, Mino-Kenudson M, Drilon A. Clinicopathlogic features of non-small-cell lung cancer harboring an NTRK gene fusion. JCO Precis Oncol 2018. [Epub 2018 Jul 23]. PMID: 30215037

19. Ou SI, Nagasaka M, Zhu VW. Liquid biopsy to identify actionable genomic alterations. Am Soc Clin Oncol Educ Book 2018;(38):978-97. PMID: 30231331

20. Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, Marcoux N, Banwait MK, Digumarthy SR, Su W, Yoda S, Riley AK, Nangia V, Lin JJ, Nagy RJ, Lanman RB, Dias-Santagata D, Mino-Kenudson M, Iafrate AJ, Heist RS, Shaw AT, Evans EK, Clifford C, Ou SI, Wolf B, Hata AN, Sequist LV. Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. Cancer Discov 2018;8:1529-39. PMID: 30257958

21. Klempner SJ, Gowen K, Lee TK, Zhu VW, Schrock AB, Miller VA, Ali SM, Ou SI. Carving out another slice of the pie: Exceptional response to single agent imatinib in an Asian female never-smoker with advanced NSCLC and a de-novo PDGFR-? N484K mutation. Lung Cancer 2018;124:86-9. PMID: 30268485

22. Zhu VW, Lu Y, Ou SI. Severe acute hepatitis in a patient receiving alectinib in ALK+ non-small-cell lung cancer: histological analysis. Clin Lung Cancer 2019;20:e77-80. PMID: 30318176

23. Zhu VW, Schrock AB, Bosemani T, Benn BS, Ali SM, Ou SI. Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation. Lung Cancer (Auckl) 2018;9:111-6. PMID: 30519133

24. Zhu VW, Ou SI. Pacific Rim redux: lorlatinib, the ultimate Jaeger? Ann Transl Med 2018;6:S40. PMID: 30613615

25. Zhu VW, Schrock AB, Ali SM, Ou SI. Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant squamous cell carcinoma of the lung and emergent MET amplification. Lung Cancer (Auckl) 2019;10:21-6. PMID: 30881166

26. Ou SI, Zhu VW. CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome. Lung Cancer 2019;130:201-7. PMID: 30885345

27. Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van Den Heuvel M, Neal J, Peled N, Fruh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 2019 May 24 [Epub ahead of print]. PMID: 31125062

28. Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, Camidge DR, Ou SI, Costa DB, Gadgeel SM, Steuer CE, Forde PM, Zhu VW, Fukuda Y, Clark JW, Janne PA, Mok T, Sholl LM, Heist RS. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer 2019;133:96-102. PMID: 31200835

29. Disel U, Madison R, Abhishek K, Chung JH, Trabucco SE, Matos AO, Frampton GM, Albacker LA, Reddy V, Karadurmus N, Benson A, Webster J, Paydas S, Cabanillas R, Nangia C, Ozturk MA, Millis SZ, Pal SK, Wilky B, Sokol ES, Gay LM, Soman S, Ganesan S, Janeway K, Stephens PJ, Zhu VW, Ou SI, Lovly CM, Gounder M, Schrock AB, Ross JS, Miller VA, Klempner SJ, Ali SM. The pan-cancer landscape of coamplification of the tyrosine kinases KIT, KDR, and PDGFRA. Oncologist 2019 Oct 11 [Epub ahead of print]. PMID: 31604903

30. Lin JJ, Schoenfeld AJ, Zhu VW, Yeap BY, Chin E, Rooney M, Plodkowski AJ, Digumarthy SR, Dagogo-Jack I, Gainor JF, Ou SI, Riely GJ, Shaw AT. Efficacy of platinum/pemetrexed combination chemotherapy in ALK-positive non-small cell lung cancer refractory to second-generation ALK inhibitors. J Thorac Oncol 2019 Oct 26 [Epub ahead of print]. PMID: 31669591

31. Zhu VW, Klempner SJ, Ou SI. A new paradigm emerges: recognizing receptor tyrosine kinase (RTK) fusions as an acquired and actionable resistant mechanism to EGFR inhibitors in EGFR-mutant lung cancer. Trends Cancer 2019;5:677-692. PMID: 31735287

32. Benn BS, Zhu VW. Multimodal bronchoscopic treatment of unresectable tracheal adenoid cystic carcinoma. Accepted by J Bronchology Interv Pulmonol

33. Zhu VW, Nagasaka M, Kubota T, Raval K, Robinette N, Armas O, Al-Holou W, Ou SI. Symptomatic CNS radiation necrosis requiring neurosurgical resection during post-second generation ALK inhibitor treatment with lorlatinib in ALK-rearranged NSCLC: A report of two cases. Accepted by Lung Cancer (Auckl)
Professional Societies
American Society of Clinical Oncology
International Association for the Study of Lung Cancer
Graduate Programs
Internal Medicine

Hematology and Oncology (IM)

Last updated
01/11/2020